Hengelage, T.

panobinostat patient study phase ketoconazole inhibitor cyp 3a inhibitor extension phase sample core phase treatment cancer period increase pharmacokinetic analysis cyp 3a hypophosphatemia phosphate cyp 3a inhibitors extension tumor interaction effect parameter fi rst dose trial event histone class result ratio lymphoma toxicity pharmacol safety deacetylase enzyme drug –drug interactions chemother baseline table evaluation difference cutaneous t-cell lymphoma 100 ll aliquot excretion concentration study drug plasma point method activity acetonitrile allele exposure cyp 3a genotype cyp enzymes panobinostat dose period 3 myeloid leukemia qc sample results urine analysis value hdac inhibitors aliquot phase i study assessment co-administration genotype 96- deep-well plate grade change novarti pharmacokinetic parameters thrombocytopenia day 1 period 1 pan-dac inhibitor panobinostat combination